{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:21:04Z","timestamp":1783603264625,"version":"3.55.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270360"],"award-info":[{"award-number":["82270360"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20231183"],"award-info":[{"award-number":["BK20231183"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2024M752700"],"award-info":[{"award-number":["2024M752700"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Project of Science and Technology Department of Jiangxi Province","award":["20204BCJ23018"],"award-info":[{"award-number":["20204BCJ23018"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Human Cell"],"DOI":"10.1007\/s13577-026-01415-y","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:05:07Z","timestamp":1783602307000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PD-1\/PD-L1 inhibitor induces systemic inflammation and alters cardiac lipid metabolism in C57BL\/6\u00a0J mice"],"prefix":"10.1007","volume":"39","author":[{"given":"Cong","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Ting","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Ran","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Hua","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Yu","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7549-9852","authenticated-orcid":false,"given":"Lan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"1415_CR1","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","volume":"372","author":"MA Postow","year":"2015","unstructured":"Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372:2006\u201317.","journal-title":"N Engl J Med"},{"key":"1415_CR2","doi-asserted-by":"publisher","first-page":"15440","DOI":"10.1038\/ncomms15440","volume":"8","author":"A Sucker","year":"2017","unstructured":"Sucker A, Zhao F, Pieper N, et al. Acquired IFNgamma resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions. Nat Commun. 2017;8:15440.","journal-title":"Nat Commun"},{"key":"1415_CR3","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12943-019-1091-2","volume":"18","author":"S Qin","year":"2019","unstructured":"Qin S, Xu L, Yi M, Yu S, Wu K, Luo S. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18:155.","journal-title":"Mol Cancer"},{"key":"1415_CR4","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158\u201368.","journal-title":"N Engl J Med"},{"key":"1415_CR5","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"SS Mahmood","year":"2018","unstructured":"Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71:1755\u201364.","journal-title":"J Am Coll Cardiol"},{"key":"1415_CR6","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"Salem JE, Manouchehri A, Moey M, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19:1579\u201389.","journal-title":"Lancet Oncol"},{"key":"1415_CR7","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1002\/ejhf.2289","volume":"23","author":"N Rubio-Infante","year":"2021","unstructured":"Rubio-Infante N, Ramirez-Flores YA, Castillo EC, Lozano O, Garcia-Rivas G, Torre-Amione G. Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis. Eur J Heart Fail. 2021;23:1739\u201347.","journal-title":"Eur J Heart Fail"},{"key":"1415_CR8","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","volume":"19","author":"AR Lyon","year":"2018","unstructured":"Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018;19:e447\u201358.","journal-title":"Lancet Oncol"},{"key":"1415_CR9","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s11936-020-00867-1","volume":"22","author":"N Dal'bo","year":"2020","unstructured":"Dal\u2019bo N, Patel R, Parikh R, et al. Cardiotoxicity of contemporary anticancer immunotherapy. Curr Treat Options Cardiovasc Med. 2020;22:62.","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"1415_CR10","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.117.030571","volume":"136","author":"M Escudier","year":"2017","unstructured":"Escudier M, Cautela J, Malissen N, et al. Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation. 2017;136:2085\u20137.","journal-title":"Circulation"},{"key":"1415_CR11","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/ejhf.2265","volume":"23","author":"NL Palaskas","year":"2021","unstructured":"Palaskas NL, Segura A, Lelenwa L, et al. Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy. Eur J Heart Fail. 2021;23:1725\u201335.","journal-title":"Eur J Heart Fail"},{"key":"1415_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.721333","volume":"8","author":"R Rikhi","year":"2021","unstructured":"Rikhi R, Karnuta J, Hussain M, et al. Immune checkpoint inhibitors mediated lymphocytic and giant cell myocarditis: uncovering etiological mechanisms. Front Cardiovasc Med. 2021;8:721333.","journal-title":"Front Cardiovasc Med"},{"key":"1415_CR13","doi-asserted-by":"crossref","unstructured":"Xia W, Chen H, Chen D, Ye Y, Xie C, Hou M. PD-1 inhibitor inducing exosomal miR-34a-5p expression mediates the cross talk between cardiomyocyte and macrophage in immune checkpoint inhibitor-related cardiac dysfunction. J Immunother Cancer. 2020; 8.","DOI":"10.1136\/jitc-2020-001293"},{"key":"1415_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00557","volume":"11","author":"A Ceschi","year":"2020","unstructured":"Ceschi A, Noseda R, Palin K, Verhamme K. Immune checkpoint inhibitor-related cytokine release syndrome: analysis of WHO global pharmacovigilance database. Front Pharmacol. 2020;11:557.","journal-title":"Front Pharmacol"},{"key":"1415_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111611","volume":"41","author":"T Won","year":"2022","unstructured":"Won T, Kalinoski HM, Wood MK, et al. Cardiac myosin-specific autoimmune T cells contribute to immune-checkpoint-inhibitor-associated myocarditis. Cell Rep. 2022;41:111611.","journal-title":"Cell Rep"},{"key":"1415_CR16","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/s41586-022-05432-3","volume":"611","author":"ML Axelrod","year":"2022","unstructured":"Axelrod ML, Meijers WC, Screever EM, et al. T cells specific for alpha-myosin drive immunotherapy-related myocarditis. Nature. 2022;611:818\u201326.","journal-title":"Nature"},{"key":"1415_CR17","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1361097","volume":"6","author":"A Reuben","year":"2017","unstructured":"Reuben A, Petaccia de Macedo M, McQuade J, et al. Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab. Oncoimmunology. 2017;6:e1361097.","journal-title":"Oncoimmunology"},{"key":"1415_CR18","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1186\/s13287-021-02504-5","volume":"12","author":"L Luo","year":"2021","unstructured":"Luo L, Yan C, Fuchi N, et al. Mesenchymal stem cell-derived extracellular vesicles as probable triggers of radiation-induced heart disease. Stem Cell Res Ther. 2021;12:422.","journal-title":"Stem Cell Res Ther"},{"key":"1415_CR19","doi-asserted-by":"publisher","first-page":"864188","DOI":"10.3389\/fcvm.2022.864188","volume":"9","author":"WW Cui","year":"2022","unstructured":"Cui WW, Ye C, Wang KX, et al. Momordica charantia-derived extracellular vesicles-like nanovesicles protect cardiomyocytes against radiation injury via attenuating DNA damage and mitochondria dysfunction. Front Cardiovasc Med. 2022;9:864188.","journal-title":"Front Cardiovasc Med"},{"key":"1415_CR20","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1186\/s12951-024-02705-z","volume":"22","author":"C Ye","year":"2024","unstructured":"Ye C, Yan C, Bian SJ, et al. Momordica charantia L.-derived exosome-like nanovesicles stabilize p62 expression to ameliorate doxorubicin cardiotoxicity. J Nanobiotechnology. 2024;22:464.","journal-title":"J Nanobiotechnology"},{"key":"1415_CR21","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1158\/2159-8290.CD-20-0856","volume":"11","author":"SC Wei","year":"2021","unstructured":"Wei SC, Meijers WC, Axelrod ML, et al. A genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention. Cancer Discov. 2021;11:614\u201325.","journal-title":"Cancer Discov"},{"key":"1415_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-021-02201-4","volume":"41","author":"Y Chen","year":"2022","unstructured":"Chen Y, Liu Y, Wang Y, et al. Prevotellaceae produces butyrate to alleviate PD-1\/PD-L1 inhibitor-related cardiotoxicity via PPARalpha-CYP4X1 axis in colonic macrophages. J Exp Clin Cancer Res. 2022;41:1.","journal-title":"J Exp Clin Cancer Res"},{"key":"1415_CR23","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1111\/bph.15984","volume":"180","author":"TG Gergely","year":"2023","unstructured":"Gergely TG, Kucsera D, Toth VE, et al. Characterization of immune checkpoint inhibitor-induced cardiotoxicity reveals interleukin-17A as a driver of cardiac dysfunction after anti-PD-1 treatment. Br J Pharmacol. 2023;180:740\u201361.","journal-title":"Br J Pharmacol"},{"key":"1415_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202310163","volume":"11","author":"T Li","year":"2024","unstructured":"Li T, Xu D, Ruan Z, et al. Metabolism\/immunity dual-regulation thermogels potentiating immunotherapy of glioblastoma through lactate-excretion inhibition and PD-1\/PD-L1 blockade. Adv Sci (Weinh). 2024;11:e2310163.","journal-title":"Adv Sci (Weinh)"},{"key":"1415_CR25","doi-asserted-by":"crossref","unstructured":"Yan C, Ye C, Wang KX, et al. Single-cell RNA sequencing dissect the immunological network of immune checkpoint inhibitors-induced myocarditis. Hum Mol Genet. 2026; 35.","DOI":"10.1093\/hmg\/ddag025"},{"key":"1415_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241411459","author":"M Watanabe","year":"2023","unstructured":"Watanabe M, Yano T, Sato T, et al. MTOR inhibitors modulate the physical properties of 3D spheroids derived from H9c2 cells. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms241411459.","journal-title":"Int J Mol Sci"},{"key":"1415_CR27","doi-asserted-by":"crossref","unstructured":"Rolver MG, Elingaard-Larsen LO, Pedersen SF. Assessing Cell Viability and Death in 3D Spheroid Cultures of Cancer Cells. J Vis Exp. 2019.","DOI":"10.3791\/59714-v"},{"key":"1415_CR28","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1161\/CIRCRESAHA.122.322264","volume":"133","author":"S Chen","year":"2023","unstructured":"Chen S, Chen J, Du W, et al. PDE10A inactivation prevents doxorubicin-induced cardiotoxicity and tumor growth. Circ Res. 2023;133:138\u201357.","journal-title":"Circ Res"},{"key":"1415_CR29","doi-asserted-by":"crossref","unstructured":"Moslehi J, Lichtman AH, Sharpe AH, Galluzzi L, Kitsis RN. Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms. J Clin Invest. 2021; 131.","DOI":"10.1172\/JCI145186"},{"key":"1415_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.940127","volume":"12","author":"OC Irabor","year":"2022","unstructured":"Irabor OC, Nelson N, Shah Y, et al. Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors. Front Oncol. 2022;12:940127.","journal-title":"Front Oncol"},{"key":"1415_CR31","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1093\/intimm\/dxq026","volume":"22","author":"J Wang","year":"2010","unstructured":"Wang J, Okazaki IM, Yoshida T, et al. PD-1 deficiency results in the development of fatal myocarditis in MRL mice. Int Immunol. 2010;22:443\u201352.","journal-title":"Int Immunol"},{"key":"1415_CR32","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/s41419-020-02778-2","volume":"11","author":"W Xia","year":"2020","unstructured":"Xia W, Zou C, Chen H, Xie C, Hou M. Immune checkpoint inhibitor induces cardiac injury through polarizing macrophages via modulating microRNA-34a\/Kruppel-like factor 4 signaling. Cell Death Dis. 2020;11:575.","journal-title":"Cell Death Dis"},{"key":"1415_CR33","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.jtho.2017.12.002","volume":"13","author":"S Du","year":"2018","unstructured":"Du S, Zhou L, Alexander GS, et al. PD-1 modulates radiation-induced cardiac toxicity through cytotoxic T lymphocytes. J Thorac Oncol. 2018;13:510\u201320.","journal-title":"J Thorac Oncol"},{"key":"1415_CR34","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00395-024-01046-0","volume":"120","author":"P Efentakis","year":"2025","unstructured":"Efentakis P, Choustoulaki A, Kwiatkowski G, et al. Early microvascular coronary endothelial dysfunction precedes pembrolizumab-induced cardiotoxicity. Preventive role of high dose of atorvastatin. Basic Res Cardiol. 2025;120:263\u201386.","journal-title":"Basic Res Cardiol"},{"key":"1415_CR35","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.122.062551","volume":"149","author":"P Ma","year":"2024","unstructured":"Ma P, Liu J, Qin J, et al. Expansion of pathogenic cardiac macrophages in immune checkpoint inhibitor myocarditis. Circulation. 2024;149:48\u201366.","journal-title":"Circulation"},{"key":"1415_CR36","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1093\/eurheartj\/ehab430","volume":"43","author":"L Michel","year":"2022","unstructured":"Michel L, Helfrich I, Hendgen-Cotta UB, et al. Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy. Eur Heart J. 2022;43:316\u201329.","journal-title":"Eur Heart J"},{"key":"1415_CR37","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1158\/2159-8290.CD-22-1180","volume":"13","author":"JE Salem","year":"2023","unstructured":"Salem JE, Bretagne M, Abbar B, et al. Abatacept\/Ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis. Cancer Discov. 2023;13:1100\u201315.","journal-title":"Cancer Discov"},{"key":"1415_CR38","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s00011-024-01979-1","volume":"74","author":"Y Chen","year":"2025","unstructured":"Chen Y, Luo Y, Liu Y, Qiu X, Luo D, Liu A. Mediation of macrophage M1 polarization dynamics change by ubiquitin-autophagy-pathway regulated NLRP3 inflammasomes in PD-1 inhibitor-related myocardial inflammatory injury. Inflamm Res. 2025;74:56.","journal-title":"Inflamm Res"},{"key":"1415_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010127","author":"Y Lu","year":"2025","unstructured":"Lu Y, Gao J, Hou Y, et al. Targeting the NLRP3 inflammasome abrogates cardiotoxicity of immune checkpoint blockers. J Immunother Cancer. 2025. https:\/\/doi.org\/10.1136\/jitc-2024-010127.","journal-title":"J Immunother Cancer"},{"key":"1415_CR40","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1161\/CIRCULATIONAHA.121.056730","volume":"146","author":"H Zhu","year":"2022","unstructured":"Zhu H, Galdos FX, Lee D, et al. Identification of pathogenic immune cell subsets associated with checkpoint inhibitor-induced myocarditis. Circulation. 2022;146:316\u201335.","journal-title":"Circulation"},{"key":"1415_CR41","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.jaccao.2020.08.007","volume":"2","author":"K Poels","year":"2020","unstructured":"Poels K, van Leent MMT, Boutros C, et al. Immune checkpoint inhibitor therapy aggravates T cell-driven plaque inflammation in atherosclerosis. JACC CardioOncology. 2020;2:599\u2013610.","journal-title":"JACC CardioOncology"},{"key":"1415_CR42","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/CJI.0b013e318247a4e7","volume":"35","author":"J Dulos","year":"2012","unstructured":"Dulos J, Carven GJ, van Boxtel SJ, et al. PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. J Immunother. 2012;35:169\u201378.","journal-title":"J Immunother"},{"key":"1415_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-7-35","volume":"7","author":"E von Euw","year":"2009","unstructured":"von Euw E, Chodon T, Attar N, et al. CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J Transl Med. 2009;7:35.","journal-title":"J Transl Med"},{"key":"1415_CR44","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1038\/s41569-023-00887-x","volume":"20","author":"J Ritterhoff","year":"2023","unstructured":"Ritterhoff J, Tian R. Metabolic mechanisms in physiological and pathological cardiac hypertrophy: new paradigms and challenges. Nat Rev Cardiol. 2023;20:812\u201329.","journal-title":"Nat Rev Cardiol"},{"key":"1415_CR45","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1093\/eurheartj\/ehab584","volume":"43","author":"G Varricchi","year":"2022","unstructured":"Varricchi G, Galdiero MR, Tocchetti CG. Novel actors on the stage of cardiac dysfunction induced by anti-PD1 oncological treatments. Eur Heart J. 2022;43:330\u20132.","journal-title":"Eur Heart J"}],"container-title":["Human Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-026-01415-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13577-026-01415-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-026-01415-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:05:08Z","timestamp":1783602308000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13577-026-01415-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":45,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["1415"],"URL":"https:\/\/doi.org\/10.1007\/s13577-026-01415-y","relation":{},"ISSN":["1749-0774"],"issn-type":[{"value":"1749-0774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"17 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"102"}}